Impact of treatment planning target volumen (PTV) size on radiation induced diarrhoea following selenium supplementation in gynecologic radiation oncology - a subgroup analysis of a multicenter, phase III trial by Muecke, Ralph et al.
RESEARCH Open Access
Impact of treatment planning target volumen
(PTV) size on radiation induced diarrhoea
following selenium supplementation in
gynecologic radiation oncology - a subgroup
analysis of a multicenter, phase III trial
Ralph Muecke
1*, Oliver Micke
2, Lutz Schomburg
3, Jens Buentzel
4, Michael Glatzel
5, Dieter Baaske
6,
Regina Berndt-Skorka
7, Franz J Prott
8, Berthold Reichl
9, Klaus Kisters
10, Ulrich Schaefer
1, Jutta Huebner
11,
Hans Th Eich
12, Guenther Kundt
13 and Irenaeus A Adamietz
14
Abstract
Background: In a previous analysis (Int J Radiat Oncol Biol Phys 70:828-835,2010), we assessed whether an adjuvant
supplementation with selenium (Se) improves Se status and reduces the radiation-induced side-effects of patients
treated by adjuvant radiotherapy (RT) for cervical and uterine cancer. Now, a potential relation between the planning
target volume (PTV) of the RT and the Se effect concerning radiation induced diarrhoea was evaluated in detail.
Methods: Whole blood Se concentrations had been measured in patients with cervical (n=11) and uterine cancer
(n=70) after surgical treatment, during, and at the end of RT. Patients with initial Se concentrations of less than 84 μg/l
were categorized as Se-deficient and randomized before RT to receive Se (as sodium selenite) per os on the days of RT,
or to receive no supplement during RT. Diarrhoea was graded according to the Common Toxicity Criteria system
(CTC, Version 2a). The evaluation of the PTV of the RT was ascertained with the help of a specialised computer-assisted
treatment planning software used for radiation planning procedure.
Results: A total of 81 patients had been randomized for the initial supplementation study, 39 of which received Se
[selenium group, SeG] and 42 serving as controls [control group, CG]. Mean Se levels did not differ between SeG and
CG upon study initiation, but were significantly higher in the SeG compared to the CG at the end of RT. The actuarial
incidence of at least CTC 2 radiation induced diarrhoea in the SeG was 20.5% compared to 44.5% in the CG (p=0.04).
The median PTV in both groups was 1302 ml (916–4608). With a PTV of <= 1302 ml (n=41) the actuarial incidence of at
least CTC 2 diarrhoea in the SeG was 22.3% (4 of 18 patients) compared to 34.8% (8 of 23 patients) in the CG (p=0.50).
In patients with a PTV of > 1302 ml (n=40) the actuarial incidence of at least CTC 2 diarrhoea in the SeG was 19.1%
(4 of 21 patients) versus 52.6% (10 of 19 patients) in the CG (p=0.046).
Conclusions: Se supplementation during RT was effective to improve blood Se status in Se-deficient cervical and
uterine cancer patients, and reduces episodes and severity of RT-induced diarrhoea. This effect was most pronounced
and significant in patients with large PTV (> 1302 ml).
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The essential trace element selenium (Se) is needed during
the biosynthesis of a number of selenocysteine (Sec)-
containing selenoproteins. Se supply by the daily nutrition
varies considerably between populations, being replete in
large areas of the US and rather deficient or sub-optimal
in many areas of central Africa, Asia and whole Europe.
Among the functionally characterized selenoproteins are a
number of enzymes crucially involved in the central
antioxidative systems of the human body, namely the
glutathione peroxidase (GPx) and the thioredoxin reduc-
tase (TRR) isoenzymes. In a number of epidemiologic ana-
lyses, Se deficiency has been associated with increased
infection risk and adverse mood states. Se has been shown
to possess cancer-preventive and cytoprotective activities
in both animal models and humans. It is well established
that Se has a key role in redox regulation and antioxidant
function, and hence in membrane integrity, energy metab-
olism and protection against DNA damage. These and
other functions are mediated through a small number of
selenoproteins encoded by 25 separate human genes [1-4].
Radio- and chemotherapy, disease-dependent alterations
of metabolism as well as the suboptimal nutrition of can-
cer patients in the clinics might aggravate the situation in
a Se-deficient patient even further, and increase the likeli-
hood of clinically relevant Se deficiency and radiation-
induced side effects [5-7].
Preliminary clinical evidence indicates that Se func-
tions as a radio- and chemoprotector with the ability to
alleviate side effects of tumour specific chemotherapy or
radiotherapy treatments [8-11].
In 2003, an English retrospective study indicated a posi-
tive correlation between initial serum Se levels and the dose
delivery of chemotherapy and outcome in patients with ag-
gressive non-Hodgkin´s lymphoma. In light of the results,
the authors hypothesized that specific selenocompounds in-
cluding methylseleninic acid and selenodiglutathione were
involved in inducing preferential cell death in lymphoma
cell lines and primary lymphoma cultures, which may be
partly attributable to an increased generation of reactive
oxygen species [12,13].
The German Working Group Trace Elements and Elec-
trolytes in Oncology (AKTE) conducted the worldwide
sole randomized phase III clinical studies to examine the
radioprotective properties of sodium selenite in radiation
oncology. The first of these randomized trials enrolled
head and neck tumour patients undergoing radiation ther-
apy [14]. A total of 39 patients were randomized into two
groups. 22 were enrolled in the selenium group (SeG) and
17 in the control group (CG). Weekly analyses were
performed and a significant reduction of dysphagia in the
SeG at the last week of irradiation (p=0.04) was observed.
This small randomized trial had shown some limited ef-
fects of Se in the prevention of ageusia (loss of taste) and
dysphagia due to radiotherapy because of head and neck
cancer. Most likely due to the small number of patients in-
cluded a clinical relevant radioprotection was not ob-
served [14].
In contrast to these data the second randomized phase
III study in postoperative gynecological patients with
supplementation of Se under radiotherapy conditions
supported the findings of Last et al. [12]; especially the
patients with higher plasma and whole blood Se levels
tolerated the side effects of radiotherapy significantly
better without any obvious impairment of survival data.
The main result of this study showed a significant bene-
fit of sodium selenite supplementation with regard to Se
deficiency and RT-induced diarrhoea in patients with
cervical and uterine cancer [15].
Aim of this study was to perform a subgroup analysis
of the data available from the initial study [15]. Specific-
ally, we wanted to examine whether there is a relation
between the PTV size and the Se effect concerning radi-
ation induced diarrhoea.
Patients and methods
The study had been approved by the International Ethics
Committee in Freiburg, Germany (No. 2000-D-7251).
Each patient had given written informed consent before
being accrued. The study had been performed in full ac-
cordance with the Declaration of Helsinki.
Patients were also assured of anonymity and of confi-
dentiality of person-related data. Besides, they were as-
sured that refusal to participate in the study would not
affect their future care in any way.
Patients
Between January 2000 and June 2006 whole blood Se con-
centrations were measured in patients with histopatho-
logically confirmed cervical and endometrial cancer after
surgical treatment. Patients with initial Se concentrations
of less than 84 μg/l were considered as Se-deficient and
randomized into the two study groups.
Treatment
External RT was delivered with a 6–18 MV linear accel-
erator. Five fractions per week were planned. Treatment
was given with a 3- to 4-field box technique. RT was
given as 3D conformal radiotherapy. CT-based treat-
ment planning was performed for all cases. The Clinical
Target Volume (CTV) encompassed the primary tumor
region and the pelvic regional lymph nodes.
During radiotherapy, patients in the verum group re-
ceived 500 μg of Se (as inorganic sodium selenite;
selenase
W) per os on the days of RT and 300 μgo fS eo n
the days without treatment until the last day of radiother-
apy. In the control group, adjuvant RT was given without
supplementation of Se.
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During treatment, levels of whole blood Se were mea-
sured after completing 50% of RT, and at the end of RT,
by means of atomic absorption spectroscopy according
to the method of Winnefeld et al. [16].
Check-ups during treatment
Patients were interviewed and examined by a physician on
a weekly basis. Concerning radiation-induced diarrhoea,
patients recorded the daily number of bowel movements
and scored the stool consistency. With the help of these
information diarrhoea was graded weekly according the
Common Toxicity Criteria system (CTC, Version 2a).
Planning Target Volume (PTV)
The Planning Target Volume (PTV) is a geometrical
concept, and it is defined to select appropriate beam size
and beam arrangements, taking into consideration the
net effect off all possible geometrical variations and inac-
curacies in order to ensure that the prescribed dose is
actually absorbed in the Clinical Target Volume (CTV).
The evaluation of the PTV was ascertained with the help
of a specialised computer-assisted treatment planning
software used for radiation planning procedure.
Endpoint
The endpoint of this subgroup analysis was to evaluate
the frequency of radiation induced diarrhoea depending
on Se supplementation and PTV.
Statistics
All data were stored and analyzed using the SPSS statis-
tical package 19.0 (SPSS Inc., Chicago, Illinois, USA).
Descriptive statistics were computed for continuous and
categorical variables. The statistics computed included
mean and standard deviations of continuous variables
and are presented as mean±SD, frequencies and relative
frequencies of categorical factors. Testing for differences
of continuous variables between the groups was accom-
plished by the 2-sample t test for independent samples
or the Mann–Whitney U test, as appropriate. For cat-
egorical variables comparisons were done by using
Fisher´s exact test. The period of time to diarrhoea was
estimated using Kaplan-Meier method. Differences be-
tween curves were assessed by Mantel´s log-rank test for
censored data. All p-values are resulting from two-sided
statistical tests and values of p<0.05 were considered to
be statistically significant.
Results
Patients
A total of 81 patients (age: 64.3 ±10.1, range: 31–80) with
carcinomas of cervix (n=11) or corpus uteri (n=70) with a
significant whole blood Se deficiency after curative
surgical treatment were randomized as described earlier
[15]. Accordingly, 39 were enrolled in the SeG and 42 in
the CG. Excluded from randomization were patients with
metastatic disease, diarrhoea before radiotherapy, radio-
chemotherapy, supplementation of Se before radiotherapy,
and patients who had undergone previous pelvic radio-
therapy. Table 1 specifies the main baseline characteristics
of the 81 patients concerning the endpoint of the current
study. Additional data concerning histology, tumor stage,
treatment before radiotherapy and brachytherapy have
been published earlier [15].
Whole blood Se levels
Before RT, the mean Se level in the SeG was 65.3 ± 13.6
μg/l and in the CG 63.2 ± 12.7 μg/l (p=0.49). Compared
to the CG we found a significant increase in the SeG
after completing 50% of RT (67.3±16.6 μg/l vs. 93.2±26.0
μg/l, p<0.001). At the end of RT, the mean Se level was
90.9±19.9 μg/l in the SeG and 61.4±15.5 μg/l in the CG
(p<0.001) (Table 2).
Incidence of at least CTC 2 radiation induced diarrhoea
The actuarial incidence of radiation-induced diarrhoea of
at least CTC 2 in the SeG was 20.5% (8 of 39 patients)
compared to 44.5% in the CG (18 of 42 patients) (p=0.04).
PTV
The median PTV in both groups was 1302 ml (916-4608).
The mean PTV in the SeG was 1604 ml compared to
1447 ml in the CG (p=0.55).
Incidence of at least CTC 2 diarrhoea depending on PTV
With a PTV of <= 1302 ml (n=41) the actuarial inci-
dence of at least CTC 2 diarrhoea in the SeG was 22.3%
(4 of 18 patients) compared to 34.8% in the CG (8 of 23
patients) (p=0.50). In contrast to those patients with a
PTV of > 1302 ml (n=40) the actuarial incidence of at
least CTC 2 diarrhoea in the SeG was 19.1% (4 of 21 pa-
tients) versus 52.6% (10 of 19 patients) in the CG
(p=0.046) (Figures 1, 2).
Table 1 Baseline characteristics of the 81 patients
enrolled in the subgroup analysis
with selenium with selenium p-value
Number 39(100%) 42(100%)
Age(Years), Median, Range 64.8(37-80) 63.8(31-80) 0.67
Cervix Uteri 4(10.2%) 7(16.6%)
Corpus Uteri 35(89.8%) 35(83.4%) 0.52
Total Dose of External
Radiotherapy in Gy 46.3(39.6-54.0) 48.0(39.6-59.2) 0.06
Planning Theatment Volume 1604(923-4608) 1447(916-3360) 0.55
(PTV)in ml
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diarrhoea according to CTC have been published and
are available for comparison [15].
Discussion
Our study analyzes the effects of Se supplementation in
a group of patients with initially low Se status after sur-
gery during RT treatment depending on PTV-size of ra-
diation therapy. Se supplementation improved the Se
status of our patients under the therapy conditions, and
yielded a significant reduction of diarrhoea as published
recently [15]. The increased biosynthesis and hence ac-
tivities of the different GPx and TRR isoenzymes might
have been responsible for these effects by an enhanced
neutralization of radiation-induced hydroperoxides and
free radicals in the small intestinal mucosa included in
the irradiation volume [5,17]. Beside the antioxidative
capacity in the healthy tissue a selective unusual activation
of wild-type p53 by Se-dependent reduction of two critical
cysteine residues by redox factor 1 (Ref 1) might have con-
tributed to the consecutive activation of DNA-repair in
healthy cells of the small intestinal mucosa [18-21]. Fur-
thermore, an increased biosynthesis of selenoprotein P,
which is responsible for Se homeostasis, transport of sel-
enium to tissues, antioxidant activities and decrease of
lipid hydroperoxides, might have further provided some
protection to the healthy cells in the irradiated tissue [22].
In addition, Se may have reduced translocation of the in-
flammatory transcription factor NFkB into the nucleus
and thereby diminished cytokine production and release
[23-25]. Finally, Se might have stimulated the regulatory
mechanisms of repopulation into the small intestinal mu-
cosa included in the irradiation volume at a time before
they were activated by irradiation [26].
Here, we provide results indicating that the radiopro-
tective effect of Se concerning radiation induced diar-
rhoea achieved significance primarily in patients with
PTV > 1302 ml. Thus, it can be speculated that in cor-
relation to a growing PTV a threshold concerning the
number of radiation induced free radicals exists. As a
consequence, it is conceivable that in patients with PTV
<=1302 ml the endogenous detoxification system works
sufficiently without the help of supplemental Se. In com-
parison, in cases with PTV >1302 ml and consecutively
expected higher count of radiation induced free radicals
we observed that Se supplementation yielded a signifi-
cant prevention of diarrhoea. This finding may be due to
a higher demand for Se-dependent protective enzymes
and an exhaustion of the Se reserve in the tumour pa-
tients if not efficiently supplemented during RT.
Unfortunately, in 2011 there is still no general recom-
mendation in favour of or against Se supplementation
for alleviating the side effects of chemotherapy, radio-
therapy and surgery in cancer patients [27]. Neverthe-
less, our results support the published findings of Last
et al. [12] and highlight that in patients with higher
blood selenium levels the tolerance of radiotherapy was
significantly better. Therefore, we strongly advocate to
take the Se status of the tumour patients under therapy
more seriously into account and to consider a respective
supplementation prior to therapy when the current Se
status appears to be insufficient [28,29].
Conclusions
Se supplementation during RT of the pelvic region is ef-
fective to improve blood Se status in Se-deficient cer-
vical and uterine cancer patients, and reduces episodes
and severity of RT-induced diarrhoea. This effect was
most pronounced and significant in patients with large
PTV (> 1302 ml).
Table 2 Whole blood Se levels in μg/l (means + 95% CI)
depending on Se supplementation
with selenium with selenium p-value
(Mean+95% of CI) (Mean+95% of CI)
Before RT 65.3(60.7-70.0) 62.2(59.4-68.2) =0.49
50% of RT 93.2(83.8-102.7) 67.3(61.6-72.5) <0.001
end of RT 90.9(81.3-95.1) 61.4(56.4-66.9) <0.001
0
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0,2
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0,4
0,5
0,6
012345678
RT-Week
p=0.50
Figure 1 Univariate analysis (log-rank) for the incidence of at
least diarrhoea CTC 2 depending on PTV <= 1302 ml
(thick curve: without Se; thin curve: with Se).
0
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p=0.046
Figure 2 Univariate analysis (log-rank) for the incidence of at
least diarrhoea CTC 2 depending on PTV > 1302 ml (thick curve:
without Se; thin curve: with Se).
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